Literature DB >> 24243776

Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE).

E J M Zirkzee1, T W J Huizinga, E L E M Bollen, M A van Buchem, H A M Middelkoop, N J A van der Wee, S le Cessie, G M Steup-Beekman.   

Abstract

The standardized mortality ratio (SMR) for systemic lupus erythematosus (SLE) is three; SMR increases to six in case of renal involvement. Up to now data on survival in case of neuropsychiatric involvement in SLE (NPSLE) have been scarce, therefore we calculated an SMR for NPSLE. Furthermore, we identified characteristics that influenced survival by Cox regression analyses. All patients suspected of NPSLE in our center since 1989 were evaluated and included in this study when a diagnosis of primary NPSLE could be established. Patient's life/death status was tracked using the civic registries. Thirty-two (19%) of the 169 included NPSLE patients died within a median follow-up period of six years (range 0.5-24 years). This resulted in a significantly increased mortality rate compared to the general population: SMR 9.5 (95% CI 6.7-13.5). Hazard ratios (HRs) were highest in patients with acute confusional state (HR 3.4) and older age at diagnosis of NPSLE (HR 1.1). A decreased mortality risk was seen with the prescription of antiplatelet therapy (HR 0.22). The time period in which NPSLE was diagnosed did not significantly influence survival. Most frequent causes of death were infection and NPSLE itself.

Entities:  

Keywords:  NPSLE; Standardized mortality ratio (SMR); neuropsychiatric lupus; prognosis; survival rate

Mesh:

Year:  2013        PMID: 24243776     DOI: 10.1177/0961203313512540

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  19 in total

1.  Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa.

Authors:  L B Lewandowski; L E Schanberg; N Thielman; A Phuti; A A Kalla; I Okpechi; P Nourse; P Gajjar; G Faller; P Ambaram; H Reuter; G Spittal; C Scott
Journal:  Lupus       Date:  2016-08-19       Impact factor: 2.911

Review 2.  Neuropsychiatric Systemic Lupus Erythematosus in Older Adults: Diagnosis and Management.

Authors:  Oshrat E Tayer-Shifman; Kathleen S Bingham; Zahi Touma
Journal:  Drugs Aging       Date:  2021-12-16       Impact factor: 3.923

Review 3.  Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers.

Authors:  Hélène Jeltsch-David; Sylviane Muller
Journal:  Nat Rev Neurol       Date:  2014-09-09       Impact factor: 42.937

Review 4.  Neuropsychiatric lupus: a mosaic of clinical presentations.

Authors:  Shaye Kivity; Nancy Agmon-Levin; Gisele Zandman-Goddard; Joab Chapman; Yehuda Shoenfeld
Journal:  BMC Med       Date:  2015-03-04       Impact factor: 8.775

Review 5.  From Systemic Inflammation to Neuroinflammation: The Case of Neurolupus.

Authors:  Mykolas Bendorius; Chrystelle Po; Sylviane Muller; Hélène Jeltsch-David
Journal:  Int J Mol Sci       Date:  2018-11-13       Impact factor: 5.923

Review 6.  Advanced and Conventional Magnetic Resonance Imaging in Neuropsychiatric Lupus.

Authors:  Nicolae Sarbu; Núria Bargalló; Ricard Cervera
Journal:  F1000Res       Date:  2015-06-23

7.  Clinical features and mortality in Chinese with lupus nephritis and neuropsychiatric lupus: A 124-patient study.

Authors:  Min Feng; Jun Lv; Sha Fu; Bo Liu; Ying Tang; Xia Wan; Peifen Liang; Yuchun Zeng; Jingao Li; Yanying Lu; Xiaomei Li; Anping Xu
Journal:  J Res Med Sci       Date:  2014-05       Impact factor: 1.852

Review 8.  Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives.

Authors:  César Magro-Checa; Elisabeth J Zirkzee; Tom W Huizinga; Gerda M Steup-Beekman
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

9.  Altered white matter microstructure in lupus patients: a diffusion tensor imaging study.

Authors:  Jessika Nystedt; Markus Nilsson; Andreas Jönsen; Petra Nilsson; Anders Bengtsson; Åsa Lilja; Jimmy Lätt; Peter Mannfolk; Pia C Sundgren
Journal:  Arthritis Res Ther       Date:  2018-02-07       Impact factor: 5.156

10.  Severe neuropsychiatric systemic lupus erythematosus successfully treated with rituximab: an alternative to standard of care.

Authors:  Elisabetta Chessa; Matteo Piga; Alberto Floris; Alessandro Mathieu; Alberto Cauli
Journal:  Open Access Rheumatol       Date:  2017-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.